Interrupted Etanercept Therapy: A New Case Report

Waqas S Abdulwahhab,Alaa S Mehair

doi:10.4236/jcdsa.2021.112007

Abstract

Psoriasis is a chronic, immune-mediated, inflammatory disease with a high prevalence in the general population (2%). The anti-tumor necrosis factor receptor etanercept is Food and Drug Administration (FDA) approved for the treatment of moderate-to-severe plaque psoriasis. Both continuous and interrupted etanercept therapy is effective and well-tolerated. This report aims to document a new case presentation of psoriasis on intermittent etanercept injection throughout 36 weeks with long-lasting sustained efficacy and no risk factor. Case Report: A 39-year-old adult male patient with long-standing chronic plaque psoriasis for 15 years duration without joint involvement started loading dose treatment of etanercept injection in whom due to his work circumstances not taken maintenance therapy and showed-up at the clinic after 36 weeks from first induction therapy when partial relapse of psoriatic lesions appear in last week with continued improvement when reintroducing loading treatment on followed-up over the next 36 weeks. Conclusion: Intermittent etanercept therapy considers effective for 36 weeks with prolonging sustained efficacy and without adverse effect.

Highlights

Case Report: A 39-year-old adult male patient with long-standing chronic plaque psoriasis for 15 years duration without joint involvement started loading dose treatment of etanercept injection in whom due to his work circumstances not taken maintenance therapy and showed-up at the clinic after 36 weeks from first induction therapy when partial relapse of psoriatic lesions appear in last week with continued improvement when re-introducing loading treatment on followed-up over the 36 weeks
Intermittent etanercept therapy considers effective for 36 weeks with prolonging sustained efficacy and without adverse effect
The soluble tumor necrosis factor receptor etanercept is approved by the Food and Drug Administration (FDA) for the treatment of moderate to severe plaque psoriasis [7]

Summary

Introduction

Immune-mediated, inflammatory disease with a high prevalence in the general population (2%) and an important impact on the quality of life [1]. Clinical trials and registries indicated that the overall efficacy of anti-TNF-α decreases over time leading to a progressive loss of patient adherence to treatment. Studies have revealed that the major reason for treatment discontinuation is the loss of efficacy, followed by adverse events [2] [3] [4] [5] [6]. The soluble tumor necrosis factor receptor etanercept is approved by the FDA for the treatment of moderate to severe plaque psoriasis [7]. A recent study demonstrated control of psoriasis symptoms after discontinuation and re-treatment with etanercept [8]. In the present case report, we are describing a 39-year-old adult male with a long-standing history of chronic plaque psoriasis who improved and sustained efficacy on just loading injection of etanercept therapy for 36 weeks followed-up. The consent form was taken from the patient about the publication of his condition

Case Report

Findings

Discussion